# US 9,040,671 B2 · Methods for cancer management targeting Co-029

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,040,671 B2
- Document ID: US9040671B2
- Status: Granted
- Kind: B2
- Application number: 13/811,353
- Filed: 2011-07-22
- Published: 2013-05-16
- Granted: 2015-05-26
- Earliest claimed: 2010-07-23
- Assignees: Institut National De La Sante Et De La Recherche Medicale (Inserm); Universite de Paris X1 Paris Sud
- Applicants: Eric Rubinstein; Céline Greco; François Le Naour; Claude Boucheix
- Inventors: Eric Rubinstein; Céline Greco; François Le Naour; Claude Boucheix
- Web page: https://patentgrep.com/patent/US9040671B2

## CPC

- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 35/00: Antineoplastic agents
- C07K 16/3046: {Stomach, Intestines}
- C12N 5/0693: {Tumour cells; Cancer cells}
- C12N 15/1138: {against receptors or cell surface proteins}
- G01N 33/57557: {of other specific parts of the body, e.g. brain}
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2310/14: interfering nucleic acids [NA]
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present disclosure relates to a Co-029 inhibitor for inhibiting the migration of cancer cells which express Co-029. The disclosure relates to a Co-029 inhibitor for the treatment of cancer and/or the prevention of cancer metastasis and pharmaceutical compositions comprising said inhibitor and provides Co-029 antibodies. The disclosure provides a method for predicting the response of a patient afflicted with or susceptible to be afflicted with cancer to a medical treatment with a Co-029 inhibitor, a method for diagnosing a cancer in a patient and a method for predicting the survival in a cancer patient.

## Claims

### Claim 1

A pharmaceutical composition comprising an inhibitor of human Co-029, wherein said inhibitor is an antibody which contains the CDRs of an antibody obtainable from the hybridoma accessible under CNCM deposit number I-4046 or I-4047 and a pharmaceutically acceptable carrier.

### Claim 2

An isolated Co-029 antibody directed against human Co-029 which is obtainable from the hybridoma accessible under CNCM deposit number I-4046 or I-4047.

### Claim 3

An isolated Co-029 antibody directed against human Co-029 which comprises the six complementarity determining region (CDR) sequences of an antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4046 or the six complementarity determining region (CDR) sequences of an antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4047.

### Claim 4 (depends on 3)

The antibody according to claim 3 further comprising the variable light (VL) chain and the variable heavy (VH) chain of an antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4046 or the variable light (VL) chain and the variable heavy (VH) chain of an antibody which is obtainable from the hybridoma accessible under CNCM deposit number I-4047.

### Claim 5 (depends on 3)

The antibody according to claim 3, wherein said antibody is a humanized antibody.

### Claim 6 (depends on 4)

The antibody according to claim 4, wherein said antibody is a humanized antibody.

### Claim 7 (depends on 3)

The isolated Co-029 monoclonal antibody directed against human Co-029 according to claim 3, wherein the variable heavy (VH) chain contains three CDRs having a sequence consisting of SEQ ID NO:2 for H-CDR1, SEQ ID NO:3 for H-CDR2 and SEQ ID NO:4 for H-CDR3 and the variable light (VL) chain contains three CDRs having a sequence consisting of SEQ ID NO:6 for L-CDR1, SEQ ID NO:7 for L-CDR2 and SEQ ID NO:8 for L-CDR3.

### Claim 8 (depends on 7)

The antibody according to claim 7, wherein the variable heavy (VH) chain region of said antibody has the amino acid sequence set forth as SEQ ID NO: 1 and the variable light (VL) chain region has the amino acid sequence set forth as SEQ ID NO: 5.